Tisagenlecleucel

Oxford, UK – 03 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, today highlights the launch of its Innovation and Technology Excellence Board (ITEB). The ITEB brings together leading experts in cell and gene therapy, scientific innovation, and advanced manufacturing. It will advise OXB on technology priorities, innovation opportunities and emerging trends that support the Company’s growth as a pure-play CDMO. The newly formed advisory board, which held its inaugural meeting last month, will identify opportunities to enhance scientific capabilities to ensure that OXB remains at the forefront of developing innovative technologies. This strategic insight will allow OXB to further enhance its value proposition to clients, while strengthening its market-leading position in the cell and gene therapy space. Dr. Frank Mathias, Chief Executive Officer of OXB, commented: “The Innovation and Technology Excellence Board marks a key step in OXB’s evolution as a pure-play CDMO focused on delivering best-in-class innovation for our clients. By bringing together some of the most respected voices in cell and gene therapy and biomanufacturing, we are creating a structure that will help us stay ahead of scientific and technological change, improve the way we work, and ultimately help our clients bring transformative therapies to patients.” Professor Dame Kay Davies DPhil FRS, Chair of OXB’s Innovation and Technology Excellence Board, added: “Cell and gene therapy continues to evolve quickly, and staying on top of that progress requires both scientific depth and external perspective. ITEB brings together a range of expertise to help OXB focus its innovation where it matters most: improving the way treatments are developed, manufactured and delivered. Our goal is to ensure that innovation leads to practical advances for OXB’s clients and better outcomes for patients.” Founding members of OXB’s Innovation and Technology Excellence Board are: Prof. Dame Kay Davies DPhil FRS (ITEB Committee Chair and Senior Independent Non-Executive Director of OXB) is among the most respected figures in human genetics, known for her research into the molecular basis of neuromuscular and neurological disease. She is Emeritus Dr. Lee’s Professor of Anatomy and Co-Director of the MDUK Oxford Neuromuscular Centre at the University of Oxford. Prof. Davies sits on the boards of UCB S.A. and Thomas White Oxford Ltd, she co-founded Summit Therapeutics plc and served as Deputy Chair of the Wellcome Trust (2013–2017). Prof. Uwe Buecheler, PhD, is a leading molecular biologist and biopharmaceutical executive with over 30 years of industry experience. He previously served as Head of the Biopharma Business Unit at Boehringer Ingelheim, overseeing global operations and the launch of more than 30 biologics. He is currently a Member of Supervisory Boards of Biotech companies and Non-Executive Director of BioPhorum, a company driving progress and fostering collaboration within the biopharmaceutical industry. He also chairs the Biopharma Cluster South Germany and advises biotech companies on CMC development and biomanufacturing strategy. Prof. Bruce Levine, PhD, is the Barbara and Edward Netter Professor in Cancer Gene Therapy and Founding Director of the Clinical Cell and Vaccine Production Facility at the University of Pennsylvania. He is co-inventor of Kymriah, the first FDA-approved CAR T cell therapy for leukaemia and lymphoma and has led pioneering first-in-human trials in cell and gene therapy. He is a co-founder of Tmunity and Capstan Therapeutics, holds over 30 US patents and has published more than 200 scientific papers. He is a Past President of the International Society for Cell and Gene Therapy and serves on the board of the Alliance for Cancer Gene Therapy. Prof. Axel Schambach, MD, PhD, is Director of the Institute of Experimental Hematology and Professor for Gene Modification of Somatic Cells at Hannover Medical School. His research focuses on the molecular pathophysiology of inborn and acquired diseases, with an emphasis on developing innovative gene therapy strategies, including novel vector systems and genome editing tools. He has received prestigious European grants for his pioneering work on gene therapies for hearing loss and is recognised for advancing precision genome editing and translational gene therapy. Prof. Schambach has contributed to a number of cell and gene therapy clinical trials. Prof. Luk Vandenberghe, PhD, is the Grousbeck Associate Professor in Gene Therapy at Harvard Medical School and Director of the Grousbeck Gene Therapy Center at Mass Eye and Ear and Mass General Brigham. A pioneer in AAV gene therapy, he co-invented AAV9 and has advanced novel vector technologies for treating neurosensory and other disorders. He has co-founded GenSight Biologics, Akouos, Affinia Therapeutics and the non-profit Odylia Therapeutics. Prof. Vandenberghe holds over 30 patents with more than 100 peer-reviewed publications in gene therapy research. Dr. Heather Preston (Observer and Independent Non-Executive Director of OXB) has over 30 years of experience in healthcare as a scientist, physician and management consultant and has been an investor in life sciences and biotechnology for more than 20 years. Over the course of her career, Dr. Preston has also served as a director on the boards of Oxford Science Enterprises plc, Karuna Pharmaceuticals and Akouos Inc. Dr. Preston also sits on the boards of Oxford Nanopore Technologies plc and Aligos Therapeutics, a Nasdaq-listed company. In addition, she is a Senior Advisor to TPG Biotech. Dr. Preston holds a degree in Medicine from the University of Oxford. The following members of OXB’s senior leadership team also sit on the Innovation and Technology Excellence Board: Dr. Frank Mathias (Chief Executive Officer of OXB) brings over 30 years of leadership experience in the biopharmaceutical and CDMO sectors. Prior to joining OXB, Dr. Mathias was previously the CEO of Rentschler Biopharma SE, which he successfully developed into a leading global, full-service CDMO. Prior to Rentschler, Dr. Mathias was CEO of Medigene AG, a publicly listed immuno-oncology company focusing on the development of T-cell-based cancer therapies. He is currently the Chairman of the Board of Directors of ArcticZymes Technologies ASA, a supplier of best-in-class enzyme technologies. Dr. Mathias has also served in senior roles at leading global pharmaceutical companies including Amgen Deutschland GmbH, Servier Deutschland GmbH and Hoechst AG and, in 2019, was awarded the title of “EY Entrepreneur of the Year” in Germany. Dr. Mathias is a pharmacist by training and completed his Doctorate in Pharmacy at Paris VI University. Thierry Cournez (Chief Operating Officer of OXB) has extensive experience in Sales, Marketing and GMP/GLP operations, with broad industry knowledge in the life science, biopharma and CDMO ecosystems. Prior to joining OXB, he served as Vice President of Global Testing Operations Bioreliance® at Merck Life Science, where he successfully managed large capacity expansion projects and held international responsibility for contract testing operations across the US, UK, Singapore and China. Prior to this, in his role as Vice President of End-to-End Bioprocessing Solutions, Mr. Cournez built and developed Merck Life Science’s End-to-End Promise Venture business unit, which involved the delivery and implementation of CDMO solutions for biopharma clients. Mr. Cournez holds an Engineer’s Degree in Biochemistry and Molecular Biology from INSA, Lyon, alongside a Master’s of Science in Molecular Biology from Paris VI University. Dr. Kyriacos Mitrophanous (Chief Innovation Officer of OXB) has over 30 years of lentiviral vector experience covering a range of technical disciplines, including the development of cell and gene therapies, delivery platform technologies, bioprocessing and analytics. Dr. Mitrophanous is a recognised world-class expert in the field, a named inventor on numerous lentiviral vector patents and an author of a number of key papers. In his current role, he is responsible for all aspects regarding client focussed innovation. He holds a PhD in Molecular Biology from University College London and has conducted post-doctoral research at the University of Oxford. Dr. Sébastien Ribault (Chief Business Officer of OXB) has over 25 years of experience across the biotechnology industry and CDMO space. Dr. Ribault was previously at Merck Life Science where he was Vice President & Head of Biologics and Viral Vector CDMO, leading Merck’s CDMO expansion project, establishing the Services business case and helping to establish the Life Science Services business unit. Prior to his 17 years with Merck Life Science, Dr. Ribault was a Gene Therapy Development Scientist at Transgene and Head of the R&D Laboratory at Hemosystem. He has a PhD in Molecular and Cellular Biology from the University of Strasbourg. -Ends- Enquiries: OXB: Dr. Kyriacos Mitrophanous, Chief Innovation Officer – T: +44 (0) 1865 783 000 / E: partnering@oxb.com ICR Healthcare:T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi About OXB OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

CHICAGO Funding cancer research isn't usually a political flashpoint. But as the Trump administration signals its desire to drastically cut the budget of the National Cancer Institute, the American Society of Clinical Oncology is finding itself forced to defend what is usually a bipartisan policy.“If implemented, these cuts would be devastating to the pace and progress of cancer research in America,“ ASCO CEO Clifford Hudis said in a Friday statement. ASCO maintains that federally funded cancer research is the single best investment our country has ever made.“ASCO's annual meeting this year provides a convincing example. A large study funded by the NCI found that adding the immunotherapy Tecentriq to a common chemotherapy regimen can halve the risk of disease recurrence or death in patients with a certain form of colon cancer. These data, said one of the researchers involved, will change clinical practice.But they may not have been as easily obtained without the help of the NCI, said Joel Saltzman, vice chair of regional oncology at the Cleveland Clinics Taussig Cancer Center, in a press conference held for reporters. This was a study that took five years to accrue patients to. It was open at 300 sites, he said. A study like this would just not have been feasible without the federal funding from the National Cancer Institute. Ned PagliaruloA $1 billion dollar posterOn Saturday, doctors and biotechnology executives got a closer look at Pfizers latest billion-dollar acquisition, a bispecific antibody from Chinas 3SBio, code-named SSGJ-707, that blocks the proteins PD-1 and VEGF.3SBio, which licensed Pfizers rights to SSGJ-707 for $1.25 billion upfront, presented mid-stage study data in a poster session that hinted at the drugs promise in non-small cell lung cancer. The Phase 2 study involved previously untreated people whose tumors express the protein PD-L1.Treatment shrank tumors in about two-thirds of participants given a dose of 10 milligrams infused every three weeks, with lower response rates at doses of 5, 20 and 30 milligrams. Nearly all patients experienced side effects, notably liver enzyme elevations and increased cholesterol. More than half on the 20 and 30 milligram doses had side effects judged to be severe or medically significant, while on lower doses only about 1 in 4 did.Researchers, led by Lin Wu of Hunan Cancer Hospital in China, wrote that the data support further evaluation of the 10 milligram dose. Four trials are listed as underway at clinicaltrials.gov, with a fifth planned.The 3SBio data came a day after Summit Pharmaceuticals and Akeso released Phase 3 data from their PD-1/VEGF combination treatment, now one of the most closely watched drugs in all of oncology. Jonathan GardnerAstraZenecas ad blitzWalk around Chicago this weekend and youre likely to see an ad for AstraZenecas cancer research, often emblazoned on the sides of bus stops. Take an Uber to McCormick Place, the convention center that houses ASCO for five days, and you might be reminded by an ad on the app that its been 10 years since the initial approval of Tagrisso, which now ranks among the top 20 most lucrative pharmaceutical products by sales.All pharma companies advertise at ASCO, of course, but AstraZeneca has a lot of talk about this year. For the seventh year in a row, the maker of Tagrisso, Imfinzi and Enhertu has trial data highlighted in the ASCO plenary session an occasion AstraZeneca executives are marking with a pin that weaves the number 7 between the A and Z of their companys logo.An AstraZeneca ad in downtown ChicagoNed Pagliarulo/BioPharma DiveData from one such highlighted study indicate that an AstraZeneca drug called camizestrant could be swapped in for so-called aromatase inhibitors as part of an initial treatment regimen for the most common form of advanced breast cancer. Aromatase inhibitors, one AstraZeneca bus stop ad reminds possibly confused Chicagoans, were state of the art in the 1990s. Then again, so were videotapes, it adds.Camizestrant is not yet approved, but AstraZeneca expects it will eventually become a major product. Its importance is reflected in its name: the cami root is a nod to the British drugmakers Cambridge laboratories, where camizestrant originated. Ned PagliaruloAn unexpected gene therapy spotlightHaydar Frangoul, a pediatric hematologist and oncologist, is used to presenting at medical meetings. But ASCO isnt the usual forum for Frangoul, who played a major role in testing the CRISPR gene editing treatment Casgevy for sickle cell disease.I was shocked they wanted to hear about sickle cell at ASCO, Frangoul said Saturday, opening a joint session on gene therapy held by ASCO and the American Association of Cancer Research.Frangoul walked the assembled cancer doctors and researchers through the study that supported Casgevys U.S. approval in December 2023. Jimi Olaghere, a patient in that study, described his life before treatment, and how Casgevy has changed it.Their reflections spotlighted what gene therapy can accomplish, even as the field falters amid waning investor interest, dried-up funding and persistent safety concerns.Its an important reminder even in oncology, which is perhaps not as often associated with gene therapy as rare diseases like sickle cell. Kymriah, a CAR-T cell treatment for leukemia, was the first therapy based on gene transfer technology to be cleared by the FDA. Five other CAR-Ts have been approved since, as have several other T cell-based medicines.More are likely coming, too. The session closed with a presentation from Katy Revzani, head of the MD Anderson Cancer Centers cell therapy institute, about her hospitals research exploring NK cell therapy, which she said could be safer and easier to produce off of the shelf. Ned Pagliarulo '